Login / Register Order My Items
Contact Us
800.227.0627
Contact Us Quote Order Login / Register
biodegradable polymers • oligo conjugation • delivery engineering

Biodegradable Polymer–Oligonucleotide Conjugation

End-to-end oligonucleotide CDMO services for biodegradable polymer–oligo conjugates, polyplex systems, and nanoparticle delivery platforms. We support feasibility through scale-up with integrated conjugation chemistry, purification, release profiling, and CMC-aligned analytics for siRNA, ASO, SSO, DNA, RNA, PNA, and PMO programs.

Talk to a Scientist See Polymer Options
PLGA / PLA / PCL / PGA Natural polysaccharides (HA, chitosan) Degradable dendrimer Covalent conjugates • Polyplex • Nanoparticles
Talk to a chemist Request a quote
Overview Polymer portfolio Conjugation chemistry Design guidance Manufacturing & QC Contact

Overview

Biodegradable polymer–oligonucleotide conjugation enables controlled delivery, release kinetics, and pharmacokinetic tuning of therapeutic nucleic acids. As an oligonucleotide CDMO, we develop custom polymer–oligo conjugates and polymer-enabled delivery systems for siRNA, ASO, SSO, DNA, RNA, PNA, and PMO programs. Our platforms support covalent polymer–oligonucleotide conjugates, biodegradable polyplex carriers, and PLGA-based nanoparticle systems engineered for defined degradation and intracellular release.

We integrate polymer selection, end-group functionalization, conjugation chemistry, purification, and analytical characterization into a unified development workflow aligned with preclinical CMC expectations. Polymer families include PLGA, PLA, PCL, PBAE polycations, degradable dendrimers, and natural polysaccharides (HA, chitosan, dextran), with stable or cleavable linker options tailored to your release mechanism.

From milligram feasibility to multi-gram scale-up, our oligo CDMO infrastructure supports controlled polymer architecture, defined stoichiometry, and release profiling to accelerate therapeutic nucleic acid development.

Quick facts

Optimal polymer design prioritizes the smallest, simplest scaffold that meets the required release profile without reducing oligonucleotide activity.

Hydrolysis

PLGA / PLA / PCL

Charge loss

PBAE polycations

Redox
Disulfide-cleavable
Enzymatic
HA / chitosan / dextran
PK Exposure
Hydrodynamic tuning

Adjust polymer MW/architecture to tune exposure and biodistribution while retaining clearance logic via degradation.

Release Trigger
Programmed unloading

Use hydrolytic, enzyme-cleavable, or reductively cleavable motifs for time- or environment-dependent release.

CMC Analytics
Defined CQAs

Quantify conjugation completeness, residual free oligo, polymer MW distribution, and release kinetics.

Conjugation & Biodegradable Polymer Delivery Architectures

Covalent Defined
1) Direct oligo–polymer conjugates

Site-specific attachment of an oligonucleotide (5′/3′/internal) to a biodegradable polymer using stable or cleavable linkers. Suitable for defined stoichiometry and controlled release designs.

Common goal: controlled release + reduced long-term polymer burden

Polyplex Biodegradable
2) Biodegradable polyplex systems

Biodegradable polycations (e.g., PBAE or degradable dendrimers) complex oligos electrostatically for uptake, then degrade/neutralize to promote intracellular “unpacking”.

Common goal: uptake + improved release with reduced polycation accumulation

NP Release
3) Polymer nanoparticles / depots

Polymer matrices (PLGA/PLA/PCL, etc.) encapsulate oligos for sustained release. Best for local/regional delivery or time-programmed systemic exposure depending on formulation.

Common goal: sustained exposure with tunable erosion/diffusion

Therapeutic Oligonucleotide–Biodegradable Polymer Architecture (schematic)
Oligonucleotide–Biodegradable Polymer Conjugation Overview
Oligonucleotide–polymer conjugation overview schematic
Conceptual overview of polymer–oligonucleotide conjugation chemistry, biodegradable polyplex systems, PLGA nanoparticle encapsulation, and release profiling workflows.

[Ligand/Shield]—(Spacer)—[Biodegradable Polymer]—(Cleavable Linker)—[Oligonucleotide]    (covalent)
(+) Polymer ⇄ [Oligo]      (polyplex; degradation → charge loss → release)
[Hydrophilic shell] ⟂ [Biodegradable core + encapsulated oligo]    (nanoparticle/depots)

Biodegradable polymer portfolio (examples)

Below is a practical selection map of biodegradable polymer families and common functionalization patterns used for oligo conjugation, crosslinking, coating, or delivery formulation.

A) Polymer families commonly used in nucleic acid programs
Family Typical role Notes
PLGA / PLA / PCL / PGA Nanoparticles, depots, coatings, conjugate scaffolds (via end-group chemistry) Hydrolysis-driven degradation; tune LA:GA ratio (PLGA), MW, architecture (multi-arm)
Poly(lactide-co-caprolactone) (PLCL) & related copolymers Elastic matrices, controlled erosion Intermediate properties between PLA and PCL; useful for mechanical tuning
Polyanhydrides Local release / surface erosion systems Surface erosion can yield more predictable release in some depot designs
PBAE (poly(β-amino esters)) Biodegradable polyplex carrier Designed to lose charge as esters cleave → promotes intracellular release
Dendrimers / dendrons (biodegradable designs) Compact multivalent carriers or conjugation scaffolds Control generation/charge; consider shielding to manage serum interactions
Natural polymers (HA, chitosan, dextran, cellulose, pectin, alginate) Targeting, hydrogels, coatings, local delivery Enzymatic degradation; batch properties vary—define DS/MW/specs early
B) Functional end-groups & bio-orthogonal handles
Functionalization Why it matters for oligos Typical use
COOH / di-COOH, NH2 / di-NH2 Simple coupling entry points EDC/NHS activation; amide formation; surface grafting
NHS-activated, maleimide, vinyl sulfone Fast, selective coupling to amines/thiols Post-synthetic oligo coupling; protein/peptide bridging
Azide, DBCO/BCN Bioorthogonal “click” assembly SPAAC modular payload swapping; mild aqueous conditions
Aldehyde, hydrazide, aminooxy Chemoselective ligations Oxime/hydrazone formation for controlled coupling
Thiol, disulfide-capable Redox-sensitive release logic Triggered intracellular release; reversible shielding
Biotin, IgG/ligand conjugated Affinity & targeting options Streptavidin capture; targeting scaffolds; assay constructs
How to request a polymer

Provide: polymer family + target MW range + end-group(s) + intended use (covalent conjugate, polyplex, nanoparticle, hydrogel) + desired degradation window (hours/days/weeks) + oligo modality and attachment site.

Conjugation chemistry (oligo ↔ polymer)

Chemistry selection should be driven by your installed oligo handle(s), polymer end-group(s), buffer compatibility, and whether the final linkage should be stable or cleavable. We can implement both post-synthetic conjugation and solid-phase handle installation to maximize site control.

Amine NHS
NHS–amine coupling

High-yield aqueous coupling to 5′/3′-amines. Avoid primary-amine buffers (e.g., Tris) during reaction.

Bond: amide

Thiol Maleimide
Maleimide–thiol coupling

Site-selective for 5′/3′-thiols. Control pH and reduce disulfide formation by handling thiols carefully.

Bond: thioether

Click SPAAC
SPAAC click (Azide–DBCO/BCN)

Bioorthogonal, copper-free click for modular assembly. Useful when payload sensitivity is a concern.

Bond: triazole

EDC COOH
Carboxyl activation (EDC/NHS)

Converts COOH polymers to active esters for coupling to amines; often used for grafting and surface coupling.

Bond: amide

Carbonyl Oxime
Aldehyde ↔ aminooxy/hydrazide

Chemoselective ligations in water; useful when orthogonality is required alongside other reactive groups.

Bond: oxime/hydrazone

Cleavable Disulfide
Redox-cleavable designs

Use disulfide exchange or disulfide-containing linkers for intracellular release logic (high GSH environments).

Trigger: reduction

Attachment site options

5′ / 3′: most common for conjugation; maintain activity by placing polymer away from functional domains.
Internal: use when both termini must remain unmodified (e.g., specific hybridization/enzymology constraints).

Technical Design Guidance for Biodegradable Polymer–Oligo Conjugates

Key design levers
  1. Degradation kinetics: match polymer erosion/linker cleavage to the therapeutic window.
  2. Charge density: polycations improve uptake but increase toxicity—use degradable charge-loss designs and shielding when needed.
  3. Architecture: linear vs multi-arm vs dendritic changes size, multivalency, and clearance profile.
  4. Site/strand selection: for duplex systems (siRNA), specify which strand is modified and where.
  5. Release mechanism: hydrolysis (time), reduction (intracellular), enzymes (microenvironment/tissue).
Common failure modes (and fixes)
  • Loss of activity: reduce polymer size, change attachment site, increase spacer length, or switch to cleavable linker.
  • Low conjugation yield: optimize pH/buffer, use activated end-groups (NHS/maleimide), add solubilizing spacer.
  • Broad analytics: define polymer MW distribution early; consider discrete spacers for handle placement.
  • Unpredictable release: move from bulk-eroding matrices to surface-erosion or triggerable linkers where appropriate.
Suggested data package

Conjugation completeness • residual free oligo • polymer MW distribution (SEC/GPC) • HPLC/UPLC purity profile • LC-MS ID (where applicable) • in-buffer + serum stability • release kinetics under relevant triggers (pH/redox/enzymes) • particle size/PDI for nanoparticle formats.

Preclinical manufacturing & QC

Biodegradable polymer formats introduce additional critical quality attributes (CQAs) beyond the oligonucleotide itself. Early CMC definition improves consistency during iteration and scale-up (from mg to multi-gram, depending on format). As a specialized oligonucleotide CDMO, we integrate conjugation chemistry, polymer engineering, purification, and analytical development under one platform to reduce technology transfer risk.

Polymer MW
Polymer specification

Define MW distribution, end-group identity, and residual monomer/solvent limits appropriate to the program stage.

Purity Separation
Purification strategy

Separate unconjugated oligo and polymer/oligo impurities using modality-appropriate chromatography.

Stability Release
Stability & release

Establish storage and handling windows; quantify release and degradation under physiologically relevant conditions.

Request a technical discussion →

FAQ

Is PLGA used for direct conjugation or mostly encapsulation?

Most programs use PLGA for encapsulated nanoparticles/depots, but end-group functionalized PLGA can also support covalent grafting or surface coupling workflows.

What’s the difference between a conjugate and a polyplex?

A conjugate is covalent and stoichiometrically defined. A polyplex is electrostatic complexation, and performance depends on charge balance, serum stability, and biodegradation-driven release.

Do biodegradable polycations reduce toxicity?

They can, because degradation can lower charge density over time and reduce accumulation. However, toxicity still depends on dose, formulation, and surface properties—so validation is essential.

Can you add a cleavable linker between polymer and oligo?

Yes. We can engineer stable or cleavable linkers (e.g., redox-cleavable motifs) based on your desired release mechanism and stability window.

Which oligo modalities are supported?

siRNA, ASO, SSO, ssDNA/dsDNA, RNA, PNA, and PMO. For duplex systems, we’ll confirm strand selection and attachment position.

What information should I send for a quote?

Polymer family + MW + end-group(s), oligo modality/sequence length, attachment site/strand, desired degradation window, and target quantity. If nanoparticle/polyplex: target particle size and buffer constraints.

More FAQ'sAll FAQ's

Talk to a Scientist

Share your modality (siRNA, ASO, PNA, PMO), intended function (covalent conjugate vs polyplex vs nanoparticle), desired degradation window, and any targeting/ligand requirements. We’ll recommend a polymer family, end-group strategy, conjugation chemistry, and an analytical plan aligned to your program stage.

End-group selection Cleavable linkers Release profiling CMC-aligned analytics
What to include
  • Oligo type and length (and strand for siRNA)
  • Attachment site (5′/3′/internal) + handle (NH2/SH/azide/alkyne)
  • Polymer family + target MW + desired end-group(s)
  • Degradation goal (hours/days/weeks) and trigger preference (hydrolysis/redox/enzymes)
  • Target quantity and timeline
Request a Quote Contact

Confidential technical consultation • Rapid feasibility • Preclinical development support

Recommended Reading

A short, practical reading list to support polymer selection, degradation design, and nucleic acid delivery performance evaluation.

Biodegradable polymer fundamentals
  • PLGA/PLA/PCL degradation kinetics: LA:GA ratio, MW, end-group effects, crystallinity
  • Bulk erosion vs surface erosion and how it changes release profiles
  • Polymer characterization: SEC/GPC, residual monomer/solvent, thermal properties
Nucleic acid delivery engineering
  • Polyplex stability vs unpacking: charge balance, buffering behavior, serum effects
  • Endosomal escape considerations and how degradable carriers influence release
  • Particle CQAs: size/PDI, surface chemistry, stability, and release testing
What to look for in papers and vendor datasheets

Prioritize sources that report polymer MW distribution, end-group identity, buffer/serum release data, and an explicit connection between degradation and oligo activity (e.g., gene knockdown, splicing correction, uptake metrics).

Selected Literature
  1. Juliano, R. L. (2018). The delivery of therapeutic oligonucleotides. Nucleic Acids Research, 46(7), 3268–3284.
  2. Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013). Delivery materials for siRNA therapeutics. Nature Materials, 12, 967–977.
  3. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012). PLGA-based nanoparticles: An overview of biomedical applications. Journal of Controlled Release, 161(2), 505–522.
  4. Lynn, D. M., & Langer, R. (2000). Degradable poly(β-amino esters): Synthesis and characterization of biodegradable cationic polymers for gene delivery. Journal of the American Chemical Society, 122(44), 10761–10768.
  5. Mintzer, M. A., & Grinstaff, M. W. (2011). Biomedical applications of dendrimers: A tutorial. Chemical Society Reviews, 40, 173–190.

These references provide foundational background on oligonucleotide delivery, biodegradable polymer systems, polyplex engineering, dendrimers, and nanoparticle-based release platforms.

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.

Greetings Researchers,

Please be advised that any information, guidelines, writeups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the designs of the products intended for their experiments before submitting
their designs to Biosynthesis for review of production feasibility.
Thank you for your understanding.

Quick Links